Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2256314/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2256314
Apr 16, 2024 - Investors are optimistic about Charles River (CRL) owing to strength in RMS and DSA segments.
0
ICLR or CRL: Which Is the Better Value Stock Right Now?
https://www.zacks.com/stock/news/2254694/iclr-or-crl-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-2254694
Apr 12, 2024 - ICLR vs. CRL: Which Stock Is the Better Value Option?
0
Charles River (CRL) Forges Collaboration With Ship of Theseus
https://www.zacks.com/stock/news/2253832/charles-river-crl-forges-collaboration-with-ship-of-theseus?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2253832
Apr 11, 2024 - Charles River (CRL) is set to perform plasmid production for Ship of Theseus.
0
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
https://www.zacks.com/stock/news/2245968/charles-river-crl-extends-gene-therapy-deal-with-nus-medicine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2245968
Mar 26, 2024 - Charles River (CRL) announces the extension of the gene therapy manufacturing alliance with NUS Medicine.
0
Charles River (CRL) Extends Gene Therapy Offering With New Pact
https://www.zacks.com/stock/news/2241549/charles-river-crl-extends-gene-therapy-offering-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241549
Mar 15, 2024 - Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2240683/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240683
Mar 14, 2024 - Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
0
Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia
https://www.zacks.com/stock/news/2237412/vanda-vnda-falls-on-fda-s-crl-to-hetlioz-snda-for-insomnia?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2237412
Mar 07, 2024 - Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.
0
Charles River (CRL) Gains From CRADL Amid Soft Market Scenario
https://www.zacks.com/stock/news/2229453/charles-river-crl-gains-from-cradl-amid-soft-market-scenario?cid=CS-ZC-FT-analyst_blog|zer_report_update-2229453
Feb 21, 2024 - Within DSA, Charles River (CRL) is currently the largest provider of outsourced drug discovery, non-clinical development and regulated safety testing services worldwide.
0
Unveiling Charles River (CRL) Q4 Outlook: Wall Street Estimates for Key Metrics
https://www.zacks.com/stock/news/2224019/unveiling-charles-river-crl-q4-outlook-wall-street-estimates-for-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm_preview-2224019
Feb 09, 2024 - Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
0
Here's Why You Should Retain Charles River (CRL) Stock Now
https://www.zacks.com/stock/news/2209712/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2209712
Jan 12, 2024 - Investors are optimistic about Charles River (CRL) owing to growth in the RMS and DSA segments and stable solvency position.
0
Pages: 12
Page 1